Core Viewpoint - Kewaunee Scientific Corporation's stock has significantly underperformed the market despite strong financial results for the first quarter of fiscal 2026, raising concerns among investors about future performance [1][13][14] Earnings & Revenue Performance - The company reported first-quarter fiscal 2026 sales of $71.1 million, a 46.9% increase from $48.4 million in the prior-year quarter [2] - Net earnings rose 41.1% to $3.1 million from $2.2 million a year ago [2] - Diluted earnings per share grew 40.5% to $1.04 from 74 cents in the same quarter last year [2] - EBITDA nearly doubled to $6.3 million from $3.3 million in the prior-year period [2] Domestic and International Sales - Domestic sales soared 53% to $54.4 million, while international sales advanced 30.2% to $16.8 million [4] - Domestic segment net earnings increased to $4.7 million compared to $2.9 million a year ago [4] - International earnings improved to $0.6 million from $0.5 million [4] Order Backlog and Working Capital - The company's order backlog stood at $205 million as of July 31, 2025, up from $159.4 million a year earlier [3] - Working capital rose to $66.7 million from $56 million a year earlier [5] - Total cash on hand increased to $20.4 million at quarter-end from $17.2 million in April 2025 [5] Debt Metrics - Short-term debt declined to $4.3 million from $4.8 million in April [5] - Long-term debt eased to $60.3 million from $60.7 million [5] - The debt-to-equity ratio improved to 0.94-to-1 from 0.99-to-1 three months earlier [5] Management Commentary - CEO Thomas D. Hull III noted that strong quarterly results were achieved amid challenging market conditions [6] - The company expects uneven quarterly performance through fiscal 2026 due to volatility in project delivery timelines [6][11] Strategic Focus - Management reiterated its commitment to growth through organic means and acquisitions, supported by investments in people, processes, and technology [7] - The integration of Nu Aire's results significantly boosted domestic sales and earnings [8][12] Corporate Segment Performance - The corporate segment continued to weigh on consolidated results, with a pre-tax net loss of $3.1 million compared to a $2 million loss a year ago [9] - Corporate segment EBITDA was negative $2.3 million, reflecting higher compliance costs and ongoing investments [9] Future Outlook - Management expects unadjusted EBITDA for fiscal 2026 to surpass that of fiscal 2025 [10] - Despite anticipated pressure on near-term earnings due to strategic investments, leadership remains confident in long-term growth prospects [11]

PART I. FINANCIAL INFORMATION Presents the unaudited condensed consolidated financial statements and related disclosures for the company [Item 1. Condensed Consolidated Financial Statements](index=4&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements) This section presents Kewaunee Scientific Corporation's unaudited condensed consolidated financial statements, including statements of operations, comprehensive earnings, stockholders' equity, balance sheets, and cash flows, along with detailed notes explaining accounting policies, significant transactions like the Nu Aire acquisition, and financial instrument valuations for the three months ended July 31, 2025, and comparative periods [Condensed Consolidated Statements of Operations](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Summarizes the company's net sales, gross profit, operating profit, and net earnings for the three months ended July 31, 2025 and 2024 | Metric | Three Months Ended July 31, 2025 ($ thousands) | Three Months Ended July 31, 2024 ($ thousands) | YoY Change (%) | | :--------------------------------- | :--------------------------------------------- | :--------------------------------------------- | :------------- | | Net sales | 71,104 | 48,393 | 46.9% | | Cost of products sold | 50,174 | 35,905 | 39.7% | | Gross profit | 20,930 | 12,488 | 67.6% | | Operating expenses | 16,120 | 9,913 | 62.6% | | Operating profit | 4,810 | 2,575 | 86.8% | | Profit before income taxes | 3,920 | 2,430 | 61.3% | | Income tax expense | 761 | 192 | 296.4% | | Net earnings | 3,159 | 2,238 | 41.2% | | Net earnings attributable to Kewaunee Scientific Corporation | 3,093 | 2,193 | 41.0% | | Basic EPS | 1.08 | 0.77 | 40.3% | | Diluted EPS | 1.04 | 0.74 | 40.5% | [Condensed Consolidated Statements of Comprehensive Earnings](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Comprehensive%20Earnings) Presents net earnings and other comprehensive income/loss, including foreign currency adjustments, for the three months ended July 31, 2025 and 2024 | Metric | Three Months Ended July 31, 2025 ($ thousands) | Three Months Ended July 31, 2024 ($ thousands) | YoY Change (%) | | :------------------------------------------------- | :--------------------------------------------- | :--------------------------------------------- | :------------- | | Net earnings | 3,159 | 2,238 | 41.2% | | Foreign currency translation adjustments | (410) | (116) | 253.4% | | Other comprehensive loss | (410) | (116) | 253.4% | | Comprehensive earnings, net of tax | 2,749 | 2,122 | 29.5% | | Comprehensive earnings attributable to Kewaunee Scientific Corporation | 2,683 | 2,077 | 29.2% | [Condensed Consolidated Statements of Stockholders' Equity](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders'%20Equity) Details changes in stockholders' equity, including retained earnings and accumulated other comprehensive loss, between April 30, 2025 and July 31, 2025 | Metric | As of July 31, 2025 ($ thousands) | As of April 30, 2025 ($ thousands) | Change ($ thousands) | | :------------------------------------------ | :-------------------------------- | :-------------------------------- | :------------------- | | Total Kewaunee Scientific Corporation Stockholders' Equity | 67,078 | 64,457 | 2,621 | | Retained Earnings | 62,012 | 58,919 | 3,093 | | Accumulated Other Comprehensive Loss | (4,213) | (3,803) | (410) | - Net earnings attributable to Kewaunee Scientific Corporation for the three months ended July 31, 2025, were **$3,093 thousand**, contributing to the increase in retained earnings[16](index=16&type=chunk) - Other comprehensive loss for the three months ended July 31, 2025, was **$(410) thousand**[16](index=16&type=chunk) [Condensed Consolidated Balance Sheets](index=8&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Outlines the company's financial position, including assets, liabilities, and equity, as of July 31, 2025 and April 30, 2025 | Metric | As of July 31, 2025 ($ thousands) | As of April 30, 2025 ($ thousands) | Change ($ thousands) | | :------------------------------------ | :-------------------------------- | :-------------------------------- | :------------------- | | Total Current Assets | 117,148 | 118,363 | (1,215) | | Total Assets | 193,486 | 194,654 | (1,168) | | Total Current Liabilities | 50,486 | 53,712 | (3,226) | | Total Liabilities | 124,617 | 128,409 | (3,792) | | Total Stockholders' Equity | 68,869 | 66,245 | 2,624 | | Cash and cash equivalents | 19,489 | 14,942 | 4,547 | | Receivables, net | 56,897 | 62,384 | (5,487) | | Inventories | 34,923 | 32,849 | 2,074 | [Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Summarizes cash flows from operating, investing, and financing activities for the three months ended July 31, 2025 and 2024 | Metric | Three Months Ended July 31, 2025 ($ thousands) | Three Months Ended July 31, 2024 ($ thousands) | Change ($ thousands) | | :------------------------------------------ | :--------------------------------------------- | :--------------------------------------------- | :------------------- | | Net cash provided by (used in) operating activities | 5,791 | (794) | 6,585 | | Net cash used in investing activities | (771) | (278) | (493) | | Net cash (used in) provided by financing activities | (1,463) | 343 | (1,806) | | Increase (decrease) in cash, cash equivalents and restricted cash | 3,277 | (752) | 4,029 | | Cash, cash equivalents and restricted cash, end of period | 20,441 | 25,186 | (4,745) | - Operating activities provided **$5,791 thousand** in cash for the three months ended July 31, 2025, a substantial improvement from **$794 thousand** used in the prior year[21](index=21&type=chunk) - Capital expenditures increased to **$771 thousand** for the three months ended July 31, 2025, from **$278 thousand** in the prior year[21](index=21&type=chunk) [Notes to Condensed Consolidated Financial Statements](index=11&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Provides detailed explanations and disclosures for the condensed consolidated financial statements, covering accounting policies, acquisitions, and financial instruments [A. Financial Information](index=11&type=section&id=A.%20Financial%20Information) Clarifies the basis of preparation for unaudited interim financial statements and their relation to the annual report - The interim financial statements are unaudited and prepared under SEC rules, condensing GAAP disclosures, and should be read in conjunction with the Company's 2025 Annual Report on Form 10-K[26](index=26&type=chunk)[27](index=27&type=chunk) - Interim results are not necessarily indicative of full-year results, and management's estimates and assumptions are subject to actual results differing[27](index=27&type=chunk)[28](index=28&type=chunk) [B. Cash, Cash Equivalents and Restricted Cash](index=11&type=section&id=B.%20Cash,%20Cash%20Equivalents%20and%20Restricted%20Cash) Details the composition of cash, cash equivalents, and restricted cash, including performance guarantee amounts - Restricted cash includes bank deposits of subsidiaries used for performance guarantees against customer orders[29](index=29&type=chunk) | Metric | July 31, 2025 ($ thousands) | April 30, 2025 ($ thousands) | | :-------------------------------------- | :-------------------------- | :--------------------------- | | Cash and cash equivalents | 19,489 | 14,942 | | Restricted cash | 952 | 2,222 | | Total cash, cash equivalents and restricted cash | 20,441 | 17,164 | [C. Nu Aire Acquisition](index=11&type=section&id=C.%20Nu%20Aire%20Acquisition) Describes the Nu Aire, Inc. acquisition, its financial impact, purchase price allocation, and pro forma information - Kewaunee Scientific Corporation acquired Nu Aire, Inc. on November 1, 2024, for **$53.0 million**, expanding its capabilities in laboratory furnishings and technical products[31](index=31&type=chunk)[32](index=32&type=chunk)[33](index=33&type=chunk) - The acquisition was funded by **$29.669 million** cash and **$23.0 million** in subordinated seller notes[32](index=32&type=chunk)[33](index=33&type=chunk) - Nu Aire contributed **$19.7 million** in revenue and **$696,000** in net earnings for the three months ended July 31, 2025[37](index=37&type=chunk) Nu Aire Purchase Price Allocation (as of July 31, 2025) | Asset/Liability | Final Allocation ($ thousands) | | :-------------------------------- | :----------------------------- | | Cash and cash equivalents | 1,245 | | Receivables | 10,650 | | Inventories | 15,522 | | Property, plant and equipment | 7,349 | | Other intangible assets | 18,600 | | Goodwill | 12,487 | | Total assets acquired | 74,088 | | Total liabilities assumed | (21,108) | | Aggregate acquisition consideration | 52,980 | Pro Forma Financial Information (Three Months Ended July 31, 2024, as if Nu Aire acquired May 1, 2023) | Metric | 2025 (actual) ($ thousands) | 2024 (pro forma) ($ thousands) | | :------------------------------------------ | :-------------------------- | :----------------------------- | | Net sales | 71,104 | 65,448 | | Net earnings | 3,093 | 4,273 | | Basic EPS | 1.08 | 1.50 | | Diluted EPS | 1.04 | 1.44 | [D. Revenue Recognition](index=14&type=section&id=D.%20Revenue%20Recognition) Explains revenue recognition policies, disaggregated revenue by type and geography, and deferred revenue balances - The majority of the Company's revenues are recognized over time as the customer receives control, with a portion recognized at a distinct point in time[41](index=41&type=chunk) Disaggregated Revenue (Three Months Ended July 31) | Revenue Type | July 31, 2025 Domestic ($ thousands) | July 31, 2025 International ($ thousands) | July 31, 2025 Total ($ thousands) | July 31, 2024 Domestic ($ thousands) | July 31, 2024 International ($ thousands) | July 31, 2024 Total ($ thousands) | | :----------- | :----------------------------------- | :---------------------------------------- | :-------------------------------- | :----------------------------------- | :---------------------------------------- | :-------------------------------- | | Over Time | 32,713 | 16,752 | 49,465 | 34,389 | 12,870 | 47,259 | | Point in Time | 21,639 | — | 21,639 | 1,134 | — | 1,134 | | Total | 54,352 | 16,752 | 71,104 | 35,523 | 12,870 | 48,393 | - Deferred revenue at July 31, 2025, was **$4,983 thousand**, with approximately **100%** expected to be recognized as revenue in the succeeding **12 months**[43](index=43&type=chunk) [E. Inventories](index=14&type=section&id=E.%20Inventories) Outlines the valuation method and composition of inventories, including finished products, work in process, and raw materials - Inventories are measured using the first-in, first-out (FIFO) method at the lower of cost or net realizable value[44](index=44&type=chunk) Inventories Composition | Inventory Type | July 31, 2025 ($ thousands) | April 30, 2025 ($ thousands) | | :------------- | :-------------------------- | :--------------------------- | | Finished products | 6,056 | 5,543 | | Work in process | 6,827 | 3,784 | | Raw materials | 22,040 | 23,522 | | Total | 34,923 | 32,849 | [F. Fair Value of Financial Instruments](index=15&type=section&id=F.%20Fair%20Value%20of%20Financial%20Instruments) Discusses fair value measurement of financial instruments and their classification within the fair value hierarchy - The carrying value of the Company's financial instruments, including cash, mutual funds, and debt, approximates their fair value[45](index=45&type=chunk) Fair Value Hierarchy (July 31, 2025) | Financial Assets | Level 1 ($ thousands) | Level 2 ($ thousands) | Total ($ thousands) | | :------------------------------------------------- | :-------------------- | :-------------------- | :------------------ | | Trading securities held in non-qualified compensation plans | 2,340 | — | 2,340 | | Cash surrender value of life insurance policies | — | 1,514 | 1,514 | | Total Financial Assets | 2,340 | 1,514 | 3,854 | | Financial Liabilities | | | | | Non-qualified compensation plans | — | 4,334 | 4,334 | | Total Financial Liabilities | — | 4,334 | 4,334 | [G. Goodwill and Other Intangible Assets](index=15&type=section&id=G.%20Goodwill%20and%20Other%20Intangible%20Assets) Details goodwill from the Nu Aire acquisition and the composition, useful lives, and amortization of other intangible assets - Goodwill of approximately **$12.5 million** was recorded from the Nu Aire Acquisition, with no impairment losses during the three months ended July 31, 2025[45](index=45&type=chunk) Intangible Assets (July 31, 2025) | Intangible Asset | Estimated Useful Life | Gross Carrying Amount ($ thousands) | Accumulated Amortization ($ thousands) | Net Book Value ($ thousands) | | :----------------------- | :-------------------- | :---------------------------------- | :------------------------------------- | :--------------------------- | | Customer relationships | **10 years** | 9,800 | (735) | 9,065 | | Trade names and trademarks | indefinite | 4,900 | — | 4,900 | | Developed technology | **7 years** | 3,900 | (418) | 3,482 | | Total | | 18,600 | (1,153) | 17,447 | Expected Future Amortization Expense (excluding trade names and trademarks) | Fiscal Year | Amortization Expense ($ thousands) | | :------------------ | :------------------------------- | | Remainder of fiscal 2026 | 1,153 | | 2027 | 1,537 | | 2028 | 1,537 | | 2029 | 1,537 | | 2030 | 1,537 | | Thereafter | 5,246 | | Total | 12,547 | [H. Long-term Debt and Other Credit Arrangements](index=16&type=section&id=H.%20Long-term%20Debt%20and%20Other%20Credit%20Arrangements) Describes long-term debt, including the PNC Loan Agreement, Subordinated Seller Notes, and other credit facilities Long-term Debt Components | Debt Type | July 31, 2025 ($ thousands) | April 30, 2025 ($ thousands) | | :---------------- | :-------------------------- | :--------------------------- | | PNC Loan Agreement | 13,000 | 13,750 | | Seller Notes | 24,380 | 23,935 | | Total long-term debt | 37,380 | 37,685 | - The PNC Loan Agreement includes a **$20.0 million** Revolving Credit Facility (unused at July 31, 2025) and a **$15.0 million** Term Loan, both maturing on November 1, 2029[49](index=49&type=chunk)[51](index=51&type=chunk) - Subordinated Seller Notes of **$23.0 million**, accruing **8%** interest per annum, mature on November 1, 2027, and are subordinate to PNC's rights[53](index=53&type=chunk)[55](index=55&type=chunk) - International subsidiaries had **$495,000** in short-term borrowings at July 31, 2025[57](index=57&type=chunk) [I. Sale-Leaseback Financing Transaction](index=17&type=section&id=I.%20Sale-Leaseback%20Financing%20Transaction) Explains the headquarters sale-leaseback as a financing transaction, detailing associated liabilities and interest expense - The sale-leaseback arrangement for the Company's headquarters was accounted for as a financing transaction due to the lease being classified as a finance lease, indicating control of the property did not transfer[60](index=60&type=chunk)[62](index=62&type=chunk) - The carrying value of the financing liability was **$27,227 thousand** at July 31, 2025, with **$807 thousand** classified as current[63](index=63&type=chunk) - Interest expense associated with the financing arrangement was **$308 thousand** for the three months ended July 31, 2025[63](index=63&type=chunk) [J. Leases](index=18&type=section&id=J.%20Leases) Provides information on right-of-use assets, lease liabilities, and future minimum payments for operating and financing leases - Right-of-use assets totaled **$12,022 thousand** at July 31, 2025, for operating and financing leases[66](index=66&type=chunk) - Operating cash paid to settle lease liabilities was **$1,040 thousand** for the three months ended July 31, 2025, and operating lease expense was **$1,458 thousand**[66](index=66&type=chunk) Future Minimum Lease Payments (July 31, 2025) | Fiscal Year | Operating ($ thousands) | Financing ($ thousands) | | :------------------ | :---------------------- | :---------------------- | | Remainder of fiscal 2026 | 2,843 | 94 | | 2027 | 3,345 | 40 | | 2028 | 2,462 | 40 | | 2029 | 2,108 | 40 | | 2030 | 1,630 | 40 | | Thereafter | 160 | 22 | | Total Minimum Lease Payments | 12,548 | 276 | | Imputed Interest | (1,403) | (45) | | Total | 11,145 | 231 | [K. Stockholders' Equity](index=19&type=section&id=K.%20Stockholders'%20Equity) Details the number of outstanding common shares and the company's share repurchase program - As of July 31, 2025, there were approximately **2,865,000 shares** of Common Stock outstanding[69](index=69&type=chunk) - The Board of Directors amended the share repurchase program on March 12, 2025, authorizing an additional **100,000 shares**[71](index=71&type=chunk) - No shares were repurchased under the program during the three months ended July 31, 2025, with **100,603 shares** remaining authorized for purchase[71](index=71&type=chunk) [L. Earnings Per Share](index=19&type=section&id=L.%20Earnings%20Per%20Share) Explains basic and diluted earnings per share calculation and reconciliation of weighted average common shares outstanding - Basic EPS is based on the weighted average number of common shares outstanding, while diluted EPS reflects the assumed exercise of outstanding options and conversion of restricted stock units (RSUs)[72](index=72&type=chunk) Reconciliation of Basic to Diluted Weighted Average Common Shares Outstanding | Metric | Three Months Ended July 31, 2025 (thousands) | Three Months Ended July 31, 2024 (thousands) | | :------------------------------------------ | :------------------------------------------- | :------------------------------------------- | | Basic | 2,851 | 2,849 | | Dilutive effect of stock options and RSUs | 112 | 118 | | Weighted average common shares outstanding - diluted | 2,963 | 2,967 | [M. Stock Options and Stock-based Compensation](index=20&type=section&id=M.%20Stock%20Options%20and%20Stock-based%20Compensation) Describes the company's stock incentive plans, RSU grants, and stock-based compensation expense - The 2023 Omnibus Incentive Plan replaced the 2017 Plan, reserving **374,633 shares** for issuance, with **291,326 shares** available at July 31, 2025[74](index=74&type=chunk) - The Company granted **72,728 RSUs** in June 2025, vesting over **three years** with service and performance components[75](index=75&type=chunk) - Stock-based compensation expense was **$431 thousand** for the three months ended July 31, 2025, with **$3,877 thousand** remaining to be recorded[75](index=75&type=chunk) [N. Income Taxes](index=20&type=section&id=N.%20Income%20Taxes) Presents income tax expense, effective tax rates, and the impact of discrete tax benefits and new tax legislation Income Tax Expense and Effective Tax Rate | Metric | Three Months Ended July 31, 2025 ($ thousands) | Three Months Ended July 31, 2024 ($ thousands) | | :-------------------- | :--------------------------------------------- | :--------------------------------------------- | | Income tax expense | 761 | 192 | | Effective tax rate | 19.4% | 7.9% | - The effective tax rate for Q1 FY2026 (**19.4%**) reflects foreign operations' tax rates and a **$303 thousand** discrete tax benefit from RSU vesting[76](index=76&type=chunk) - The U.S. government enacted the One Big Beautiful Bill Act (OBBBA) on July 4, 2025, and the Company is evaluating its potential impact on future tax obligations[78](index=78&type=chunk) [O. Segment Information](index=21&type=section&id=O.%20Segment%20Information) Provides financial data disaggregated by domestic and international operating segments, evaluated by earnings before income taxes - The Company operates in two business segments: Domestic (including the Nu Aire acquisition) and International, with the CEO evaluating performance based on earnings before income taxes[79](index=79&type=chunk)[80](index=80&type=chunk) Segment Financial Information (Three Months Ended July 31, 2025 vs. 2024) | Metric | Domestic Operations 2025 ($ thousands) | International Operations 2025 ($ thousands) | Total 2025 ($ thousands) | Domestic Operations 2024 ($ thousands) | International Operations 2024 ($ thousands) | Total 2024 ($ thousands) | | :------------------------------------ | :------------------------------------- | :------------------------------------------ | :----------------------- | :------------------------------------- | :------------------------------------------ | :----------------------- | | Revenues from external customers | 54,352 | 16,752 | 71,104 | 35,523 | 12,870 | 48,393 | | Depreciation and amortization | 1,428 | 96 | 1,549 | 662 | 107 | 815 | | Interest expense | 313 | 13 | 1,058 | 441 | 21 | 472 | | Earnings (loss) before income taxes | 5,835 | 1,143 | 3,920 | 3,635 | 787 | 2,430 | | Segment assets | 153,302 | 40,184 | 193,486 | 90,235 | 41,783 | 132,018 | [P. New Accounting Standards](index=22&type=section&id=P.%20New%20Accounting%20Standards) Discusses recently issued accounting pronouncements and their expected impact on financial statements - ASU 2023-09, "Improvements for Income Tax Disclosures," is effective for fiscal year 2026, with no significant impact expected[82](index=82&type=chunk) - ASU 2024-03/2025-01, "Expense Disaggregation Disclosures," is effective for annual disclosures in fiscal year 2028 and interim disclosures in fiscal year 2029, with no significant impact expected[83](index=83&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=22&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) This section provides management's perspective on the Company's financial performance and condition, highlighting the impact of the Nu Aire acquisition on sales and gross profit, discussing liquidity, and outlining the outlook amidst market challenges and strategic growth initiatives [Acquisition of Nu Aire, Inc.](index=22&type=section&id=Acquisition%20of%20Nu%20Aire,%20Inc.) Details the strategic rationale and financial aspects of the Nu Aire acquisition, expanding product offerings - The Nu Aire acquisition, completed November 1, 2024, for **$55.0 million**, significantly expands the Company's product portfolio to include biological safety cabinets, CO2 incubators, and ultralow freezers[85](index=85&type=chunk)[86](index=86&type=chunk) - This acquisition accelerates the Company's vision of becoming a market leader in laboratory furniture and technical products by combining capabilities and leveraging Nu Aire's established distribution partners[87](index=87&type=chunk) [Critical Accounting Estimates](index=22&type=section&id=Critical%20Accounting%20Estimates) Confirms no material changes to critical accounting estimates since the last annual report, except as noted - There have been no material changes to the Company's critical accounting estimates since the 2025 Annual Report on Form 10-K, beyond those set forth in this quarterly report[88](index=88&type=chunk) [Results of Operations](index=23&type=section&id=Results%20of%20Operations) Analyzes key financial performance indicators like sales, gross profit, operating expenses, and net earnings for the three months ended July 31, 2025 and 2024 Key Financial Performance Indicators (Three Months Ended July 31) | Metric | 2025 ($ thousands) | 2024 ($ thousands) | YoY Change ($ thousands) | YoY Change (%) | | :-------------------------- | :----------------- | :----------------- | :----------------------- | :------------- | | Sales | 71,104 | 48,393 | 22,711 | 46.9% | | Domestic Sales | 54,352 | 35,523 | 18,829 | 53.0% | | International Sales | 16,752 | 12,870 | 3,882 | 30.2% | | Gross Profit Margin | 29.4% | 25.8% | 3.6 pp | - | | Operating Expenses | 16,120 | 9,913 | 6,207 | 62.6% | | Interest Expense | 1,058 | 472 | 586 | 124.2% | | Income Tax Expense | 761 | 192 | 569 | 296.4% | | Net Earnings | 3,093 | 2,193 | 900 | 41.0% | | Diluted EPS | 1.04 | 0.74 | 0.30 | 40.5% | - Domestic sales increased **53.0%** primarily due to the Nu Aire acquisition, while International sales increased **30.2%** due to large project deliveries[89](index=89&type=chunk) - The Company's order backlog was **$205.0 million** at July 31, 2025, compared to **$159.4 million** at July 31, 2024[90](index=90&type=chunk) [Liquidity and Capital Resources](index=23&type=section&id=Liquidity%20and%20Capital%20Resources) Discusses liquidity sources, working capital, and cash flows from operating, investing, and financing activities - Principal liquidity sources are funds from operating activities and the new PNC Revolving Credit Facility, which replaced the terminated Mid Cap Revolving Credit Facility[97](index=97&type=chunk) Working Capital and Ratios | Metric | July 31, 2025 ($ thousands) | April 30, 2025 ($ thousands) | | :-------------------------------- | :-------------------------- | :--------------------------- | | Working Capital | 66,662 | 64,651 | | Ratio of Current Assets to Current Liabilities | 2.3-to-1.0 | 2.2-to-1.0 | - Operating activities provided **$5,791 thousand** in cash, driven by decreases in receivables, partially offset by increases in inventories and decreases in accounts payable[99](index=99&type=chunk) - Investing activities used **$771 thousand** for capital expenditures, and financing activities used **$1,463 thousand**, primarily for long-term debt servicing[99](index=99&type=chunk) [Outlook](index=24&type=section&id=Outlook) Provides management's expectations for future performance, including project timelines, backlog, and strategic growth initiatives - The Company anticipates some volatility in project delivery timelines for fiscal year 2026 but maintains a strong overall backlog of **$205.0 million**[101](index=101&type=chunk)[90](index=90&type=chunk) - Management is focused on organic and inorganic growth, making strategic investments in people, processes, and technology to support sustainable growth[102](index=102&type=chunk) - The Company believes its strategic investments and healthy backlog position it well to manage short-term headwinds and ensure long-term business health[102](index=102&type=chunk) [Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995](index=24&type=section&id=Safe%20Harbor%20Statement%20under%20the%20Private%20Securities%20Litigation%20Reform%20Act%20of%201995) Warns about forward-looking statements, outlining risks and uncertainties that could cause actual results to differ - The document contains forward-looking statements subject to known and unknown risks, uncertainties, and assumptions that could significantly impact results[103](index=103&type=chunk) - Factors that could cause differences include the ability to realize Nu Aire acquisition benefits, competitive and economic conditions, customer demands, technological changes, international operations risks, and raw material costs[103](index=103&type=chunk) - The Company assumes no obligation to update any forward-looking statements[103](index=103&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=25&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) States no material changes to market risk disclosures from the most recent annual report - No material changes to market risk disclosures compared to the 2025 Annual Report on Form 10-K[104](index=104&type=chunk) [Item 4. Controls and Procedures](index=25&type=section&id=Item%204.%20Controls%20and%20Procedures) Reports on the effectiveness of disclosure controls and procedures and the ongoing integration of Nu Aire into the control environment - As of July 31, 2025, the Company's disclosure controls and procedures were deemed adequate and effective by management, including the CEO and CFO[105](index=105&type=chunk) - The Company is integrating Nu Aire into its systems and control environment, monitoring and maintaining appropriate internal control over financial reporting during this process[106](index=106&type=chunk) - No other significant changes in internal control over financial reporting occurred during the quarter[106](index=106&type=chunk) PART II. OTHER INFORMATION Contains additional information not covered in financial statements, including risk factors, equity sales, and exhibits [Item 1A. Risk Factors](index=26&type=section&id=Item%201A.%20Risk%20Factors) Refers to previously disclosed risk factors and notes any updates or new factors impacting the company's business - No material changes to risk factors from the 2025 Annual Report on Form 10-K, except as noted in this quarterly report[109](index=109&type=chunk) - Various known or unknown factors could materially and adversely affect the Company's business, financial condition, operating results, and stock price[109](index=109&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=26&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) Reports on unregistered sales of equity securities and details the company's share repurchase activities - No unregistered sales of equity securities occurred during the period[110](index=110&type=chunk) - The Company did not purchase any shares under its share repurchase program during the three months ended July 31, 2025, with **100,603 shares** remaining authorized for purchase[111](index=111&type=chunk) [Item 5. Other Information](index=26&type=section&id=Item%205.%20Other%20Information) Discloses information regarding Rule 10b5-1 trading arrangements by directors and executive officers - No directors or officers adopted or terminated Rule 10b5-1 or non-Rule 10b5-1 trading arrangements during the three months ended July 31, 2025[113](index=113&type=chunk) [Item 6. Exhibits](index=27&type=section&id=Item%206.%20Exhibits) Lists all documents filed as exhibits to the Form 10-Q, including certifications and financial data in XBRL format - Exhibits include bylaws, CEO/CFO certifications (Sarbanes-Oxley Act Sections 302 and 906), and Inline XBRL documents for financial data[116](index=116&type=chunk) SIGNATURE Confirms the official signing of the report by an authorized financial officer - The report was signed by Donald T. Gardner III, Vice President, Finance and Chief Financial Officer, on behalf of Kewaunee Scientific Corporation on September 12, 2025[118](index=118&type=chunk)

Company Overview - Kewaunee Scientific Corporation is a leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products, with a history dating back to 1906 [4] - The company offers a range of products including steel and wood casework, fume hoods, modular systems, workstations, biological safety cabinets, and epoxy resin surfaces [4] - Kewaunee operates manufacturing facilities in Statesville, North Carolina, and Bangalore, India, serving both domestic and international markets [4] Recent Developments - J. Jette Campbell has been appointed to Kewaunee's Board of Directors effective September 10, 2025 [1] - Campbell brings extensive experience from leadership roles at global companies such as PepsiCo and Frito-Lay, and has a background in guiding organizations through growth and transformation [2] - The company aims to leverage Campbell's expertise in building materials and furniture manufacturing to enhance its strategic planning and decision-making processes [3] Strategic Focus - Kewaunee is focused on accelerating growth through both organic and inorganic means, emphasizing thoughtful capital allocation and operational improvement [3] - The company is committed to delivering exceptional customer experiences as it expands its global footprint [3] - The recent acquisition of Nu Aire, a manufacturer of laboratory products, complements Kewaunee's existing portfolio and supports its growth strategy [4]

[Fiscal Year 2026 First Quarter Highlights](index=1&type=section&id=Fiscal%20Year%202026%20First%20Quarter%20Highlights) Kewaunee Scientific reported strong Q1 FY2026 results with significant sales and earnings growth, improved financial position, and positive segment performance, driven by the Nu Aire acquisition [Consolidated Financial Performance](index=1&type=section&id=Consolidated%20Financial%20Performance) Kewaunee Scientific reported strong consolidated results for Q1 FY2026, with significant increases in sales, pre-tax earnings, net earnings, and EBITDA compared to the prior year, driven by the Nu Aire acquisition and improved operational efficiency Consolidated Financial Highlights | Metric | Q1 FY2026 ($ in thousands) | Q1 FY2025 ($ in thousands) | Change (%) | | :----- | :------------------------- | :------------------------- | :--------- | | Sales | $71,104 | $48,393 | 46.9% | | Pre-tax Earnings | $3,920 | $2,430 | 61.3% | | Net Earnings | $3,093 | $2,193 | 41.1% | | EBITDA | $6,320 | $3,325 | 90.1% | | Diluted EPS | $1.04 | $0.74 | 40.5% | | Order Backlog (July 31, 2025) ($ million) | $205.0 | $159.4 (July 31, 2024) | 28.6% | | Order Backlog (April 30, 2025) ($ million) | $205.0 | $214.6 | -4.5% | [Segment Performance Overview](index=1&type=section&id=Segment%20Performance%20Overview) Both Domestic and International segments showed strong sales and earnings growth, while the Corporate segment experienced an increased pre-tax net loss due to strategic investments in its platform [Domestic Segment](index=1&type=section&id=Domestic%20Segment) The Domestic segment achieved significant sales and earnings growth, driven by the Nu Aire acquisition and operational improvements Domestic Segment Financials | Metric | Q1 FY2026 ($ in thousands) | Q1 FY2025 ($ in thousands) | Change (%) | | :----- | :------------------------- | :------------------------- | :--------- | | Sales | $54,352 | $35,523 | 53.0% | | Net Earnings | $4,722 | $2,871 | 64.5% | | EBITDA | $7,576 | $4,738 | 59.9% | - Growth was driven by the incorporation of Nu Aire's results, steady manufacturing volumes, improved productivity, and cost management actions[4](index=4&type=chunk) [International Segment](index=1&type=section&id=International%20Segment) The International segment experienced strong sales and earnings growth due to reduced customer site delays International Segment Financials | Metric | Q1 FY2026 ($ in thousands) | Q1 FY2025 ($ in thousands) | Change (%) | | :----- | :------------------------- | :------------------------- | :--------- | | Sales | $16,752 | $12,870 | 30.2% | | Net Earnings | $643 | $463 | 38.9% | | EBITDA | $1,055 | $696 | 51.6% | - Increased deliveries and billings were a result of decreasing customer site delays experienced during most of the prior fiscal year[5](index=5&type=chunk) [Corporate Segment](index=1&type=section&id=Corporate%20Segment) The Corporate segment's pre-tax net loss increased due to strategic investments in its platform and higher compliance costs Corporate Segment Financials | Metric | Q1 FY2026 ($ in thousands) | Q1 FY2025 ($ in thousands) | Change | | :----- | :------------------------- | :------------------------- | :----- | | Pre-tax Net Loss | $3,058 | $1,992 | Increased Loss | | EBITDA | ($2,311) | ($2,109) | Increased Negative | - Increased costs in the current year period are related to strategic investments in the Corporate platform, including increased compliance costs for anticipated Sarbanes-Oxley 404(b) requirements and investments in people, processes, and technology to support future growth[7](index=7&type=chunk) [Financial Position Snapshot](index=2&type=section&id=Financial%20Position%20Snapshot) The company improved its cash position and working capital while slightly reducing both short-term and long-term debt, leading to a lower debt-to-equity ratio compared to the previous quarter Key Financial Position Metrics | Metric | July 31, 2025 ($ in thousands) | April 30, 2025 ($ in thousands) | Change | | :----- | :----------------------------- | :----------------------------- | :----- | | Total Cash on Hand | $20,441 | $17,164 | Up $3,277 | | Working Capital | $66,662 | $64,651 | Up $2,011 | | Short-term Debt | $4,294 | $4,773 | Down $479 | | Long-term Debt | $60,269 | $60,730 | Down $461 | | Debt-to-Equity Ratio | 0.94-to-1 | 0.99-to-1 | Improved | | Debt-to-Equity Ratio (net of sale-leaseback) | 0.54-to-1 | 0.57-to-1 | Improved | [Management Commentary and Business Outlook](index=2&type=section&id=Management%20Commentary%20and%20Business%20Outlook) Management highlights solid Q1 performance, acknowledges project delivery volatility, and outlines strategic investments for long-term growth, expecting improved FY2026 unadjusted EBITDA [CEO's Remarks and Outlook](index=2&type=section&id=CEO%27s%20Remarks%20and%20Outlook) CEO Thomas D. Hull III highlighted solid Q1 performance despite challenging market conditions but anticipates uneven quarterly performance for FY2026 due to project delivery timeline volatility. The company is focused on strategic investments for sustainable long-term growth, expecting better unadjusted EBITDA for FY2026 than FY2025 despite near-term pressure on earnings - Domestic and International segments delivered **solid financial performance in Q1** despite challenging market conditions (uncertain government policy, evolving tariff structures, geopolitical upheaval)[10](index=10&type=chunk) - Overall backlog remains near historically high levels, but volatility in project delivery timelines is expected to cause **uneven quarterly performance for the balance of fiscal year 2026**, likely starting in Q2[10](index=10&type=chunk) - Kewaunee is focused on organic and inorganic growth, making strategic investments in people, processes, and technology, which will place pressure on near-term earnings but position the company for rapid and sustained long-term growth[10](index=10&type=chunk) - Despite anticipated uneven quarterly performance and increasing strategic investment, the company expects to deliver **better unadjusted EBITDA in fiscal year 2026 than in fiscal year 2025**[10](index=10&type=chunk) [Non-GAAP Financial Measures](index=3&type=section&id=Non-GAAP%20Financial%20Measures) This section provides reconciliations for non-GAAP measures like EBITDA and adjusted net earnings, clarifying their calculation and purpose as supplemental financial information [EBITDA and Segment EBITDA Reconciliation](index=3&type=section&id=EBITDA%2C%20Segment%20EBITDA%2C%20Adjusted%20EBITDA%2C%20and%20Adjusted%20Segment%20EBITDA%20Reconciliation) This section provides a detailed reconciliation of Net Earnings (Loss) to EBITDA and Adjusted EBITDA for consolidated and segment levels for Q1 FY2026 and Q1 FY2025, highlighting adjustments for interest, taxes, depreciation, amortization, and professional/other fees related to the Nu Aire acquisition and integration Consolidated EBITDA and Adjusted EBITDA Reconciliation | Metric (Consolidated) | Q1 FY2026 ($ in thousands) | Q1 FY2025 ($ in thousands) | | :-------------------- | :------------------------- | :------------------------- | | Net Earnings | $3,093 | $2,193 | | Interest Expense | $1,058 | $472 | | Interest Income | ($141) | ($347) | | Income Taxes | $761 | $192 | | Depreciation and Amortization | $1,549 | $815 | | **EBITDA** | **$6,320** | **$3,325** | | Professional & Other Fees | $224 | $730 | | **Adjusted EBITDA** | **$6,544** | **$4,055** | - Professional and other fees in Q1 FY2025 related to the Nu Aire acquisition, while Q1 FY2026 fees related to the integration of Nu Aire[11](index=11&type=chunk) [Adjusted Consolidated Statement of Operations Reconciliation](index=4&type=section&id=Adjusted%20Consolidated%20Statement%20of%20Operations%20Reconciliation) This reconciliation adjusts the consolidated statement of operations for Q1 FY2026 and Q1 FY2025 to exclude professional and other fees related to the Nu Aire integration, providing adjusted net earnings and diluted EPS figures Adjusted Consolidated Statement of Operations | Metric (Consolidated) | As Reported 2025 ($ in thousands) | Professional & Other Fees 2025 ($ in thousands) | Adjusted 2025 ($ in thousands) | Adjusted 2024 ($ in thousands) | | :-------------------- | :-------------------------------- | :---------------------------------------------- | :----------------------------- | :----------------------------- | | Net sales | $71,104 | $— | $71,104 | $48,393 | | Gross profit | $20,930 | $— | $20,930 | $12,488 | | Operating expenses | $16,120 | $224 | $15,896 | $9,183 | | Operating profit | $4,810 | $224 | $5,034 | $3,305 | | Profit before income taxes | $3,920 | $224 | $4,144 | $3,160 | | Income tax (benefit) expense | $761 | $49 | $810 | $345 | | Net earnings attributable to Kewaunee Scientific Corporation | $3,093 | $175 | $3,268 | $2,770 | | Diluted EPS | $1.04 | $0.06 | $1.10 | $0.93 | - Adjustments for professional and other fees in Q1 FY2026 (including estimated tax impact) relate to the integration of the newly acquired subsidiary, Nu Aire[12](index=12&type=chunk) [Explanation of Non-GAAP Measures](index=5&type=section&id=About%20Non-GAAP%20Measures) This section clarifies the company's use of non-GAAP financial measures like adjusted net earnings, adjusted EPS, EBITDA, and Adjusted EBITDA, explaining their calculation and purpose as supplemental information for investors to understand financial and business trends, while emphasizing they are not GAAP alternatives - Adjusted net earnings and adjusted net earnings per share are GAAP net earnings adjusted for professional and other fees related to the integration of Nu Aire, Inc., and the corresponding tax impact[13](index=13&type=chunk) - EBITDA and Segment EBITDA are calculated as net earnings (loss), less interest expense and interest income, income taxes, depreciation, and amortization[14](index=14&type=chunk) - Adjusted EBITDA and Adjusted Segment EBITDA further exclude professional and other fees related to Nu Aire integration[14](index=14&type=chunk) - These non-GAAP measures provide useful information to investors for comparing performance consistently across companies, but should not be considered alternatives to GAAP net earnings or operating cash flows[13](index=13&type=chunk)[14](index=14&type=chunk) [Company Overview](index=5&type=section&id=Company%20Overview) Kewaunee Scientific, a global leader in laboratory furniture, recently acquired Nu Aire, a key manufacturer of biological safety cabinets, expanding its product portfolio and market reach [About Kewaunee Scientific](index=5&type=section&id=About%20Kewaunee%20Scientific) Founded in 1906, Kewaunee Scientific Corporation is a global leader in designing, manufacturing, and installing laboratory, healthcare, and technical furniture products, with manufacturing facilities in the US and India and sales offices worldwide - Kewaunee Scientific Corporation, founded in 1906, is a **global leader** in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products[15](index=15&type=chunk) - Products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks[15](index=15&type=chunk) - Headquarters in Statesville, NC, with sales offices in the US, India, Saudi Arabia, and Singapore, and manufacturing facilities in Statesville (3) and Bangalore, India (1)[15](index=15&type=chunk) [About Nu Aire](index=5&type=section&id=Kewaunee%20Scientific%27s%20newly%20acquired%20subsidiary%2C%20Nu%20Aire) Nu Aire, acquired by Kewaunee Scientific, is a leading manufacturer of biological safety cabinets, CO2 incubators, ultralow freezers, and other essential laboratory products, complementing Kewaunee's portfolio, with headquarters and manufacturing in Minnesota - Nu Aire, founded in 1971 and newly acquired by Kewaunee Scientific, is a **leading manufacturer** of biological safety cabinets, CO2 incubators, ultralow freezers, and other essential laboratory products[16](index=16&type=chunk) - Headquarters and manufacturing facilities are in Plymouth, Minnesota, with additional manufacturing in Long Lake, Minnesota, and partnerships in the Netherlands and China[16](index=16&type=chunk) [Forward-Looking Statements](index=5&type=section&id=Forward-Looking%20Statements) This section provides a standard disclaimer regarding forward-looking statements, outlining various risks and uncertainties that could cause actual results to differ materially from projections [Risks and Disclaimers](index=5&type=section&id=Risks%20and%20Disclaimers) This section contains a standard disclaimer regarding forward-looking statements, outlining various known and unknown risks, uncertainties, and assumptions that could cause actual results to differ materially from projections, including those related to the Nu Aire acquisition, economic conditions, customer demands, and international operations. The company disclaims any obligation to update these statements - The press release contains 'forward-looking statements' subject to known and unknown risks, uncertainties, assumptions, and other important factors that could significantly impact results[17](index=17&type=chunk)[18](index=18&type=chunk) - Factors include the ability to realize benefits from the Nu Aire acquisition, competitive and economic conditions, supply disruptions, changes in customer demands, technological changes, dependence on delivery schedules, international operation risks (e.g., currency fluctuations), regulatory changes, raw material costs, and Force Majeure events[18](index=18&type=chunk) - The company assumes no obligation to update any forward-looking statements[18](index=18&type=chunk) [Condensed Consolidated Financial Statements](index=7&type=section&id=Condensed%20Consolidated%20Financial%20Statements) This section presents the unaudited condensed consolidated statements of operations and balance sheets for the specified periods, detailing key financial performance and position [Statements of Operations](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) This section presents the unaudited condensed consolidated statements of operations for the three months ended July 31, 2025, and 2024, detailing net sales, cost of products sold, gross profit, operating expenses, and net earnings Condensed Consolidated Statements of Operations | Metric ($ in thousands) | July 31, 2025 | July 31, 2024 | | :-------------------- | :------------ | :------------ | | Net sales | $71,104 | $48,393 | | Cost of products sold | $50,174 | $35,905 | | Gross profit | $20,930 | $12,488 | | Operating expenses | $16,120 | $9,913 | | Operating profit | $4,810 | $2,575 | | Profit before income taxes | $3,920 | $2,430 | | Net earnings attributable to Kewaunee Scientific Corporation | $3,093 | $2,193 | | Diluted EPS | $1.04 | $0.74 | [Balance Sheets](index=8&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) This section provides the unaudited condensed consolidated balance sheets as of July 31, 2025, and April 30, 2025, detailing assets, liabilities, and stockholders' equity, showing changes in cash, receivables, and debt Condensed Consolidated Balance Sheets | Metric ($ in thousands) | July 31, 2025 | April 30, 2025 | | :-------------------- | :------------ | :------------- | | Cash and cash equivalents | $19,489 | $14,942 | | Total Current Assets | $117,148 | $118,363 | | Total Assets | $193,486 | $194,654 | | Total Current Liabilities | $50,486 | $53,712 | | Total Liabilities | $124,617 | $128,409 | | Total Stockholders' Equity | $68,869 | $66,245 |

Core Insights - Kewaunee Scientific Corporation reported a strong financial performance for the first quarter of fiscal year 2026, with significant increases in sales, earnings, and EBITDA compared to the prior year [2][9]. Financial Performance - Sales for the first quarter were $71,104,000, a 46.9% increase from $48,393,000 in the same quarter last year [2]. - Pre-tax earnings rose to $3,920,000, up 61.3% from $2,430,000 in the prior year [2]. - Net earnings increased to $3,093,000 compared to $2,193,000 in the previous year [2]. - EBITDA for the quarter was $6,320,000, compared to $3,325,000 in the prior year [2]. Segment Performance - Domestic sales reached $54,352,000, a 53.0% increase from $35,523,000 in the prior year [4]. - International sales were $16,752,000, reflecting a 30.2% increase from $12,870,000 in the previous year [5]. - The domestic segment's net earnings were $4,722,000, up from $2,871,000 in the prior year [4]. - The international segment's net earnings increased to $643,000 from $463,000 in the previous year [5]. Order Backlog - The company's order backlog was $205.0 million as of July 31, 2025, compared to $159.4 million on July 31, 2024, and $214.6 million on April 30, 2025 [3]. Corporate Segment - The corporate segment reported a pre-tax net loss of $3,058,000, compared to a loss of $1,992,000 in the prior year [6]. - Corporate segment EBITDA was ($2,311,000), slightly worse than ($2,109,000) in the previous year [6]. Cash and Debt Position - Total cash on hand was $20,441,000, up from $17,164,000 on April 30, 2025 [7]. - Short-term debt decreased to $4,294,000 from $4,773,000 on April 30, 2025 [8]. - Long-term debt was $60,269,000, down from $60,730,000 on April 30, 2025 [8]. Management Commentary - The CEO noted solid performance despite challenging market conditions and indicated expectations of volatility in project delivery timelines for the remainder of fiscal year 2026 [9]. - The company is focused on both organic and inorganic growth, with strategic investments in people, processes, and technology to support future growth [9].

Core Insights - Kewaunee Scientific Corporation will participate in the 2025 Arablab Live tradeshow and conference in Dubai from September 23-25 [1] - The company will showcase its integrated expertise in laboratory infrastructure, biosafety, and healthcare environments, alongside its newly acquired subsidiary NuAire and healthcare brand EVERHUTCH [2][4] Company Overview - Kewaunee Scientific Corporation, founded in 1906, is a global leader in designing, manufacturing, and installing laboratory and healthcare furniture products [5] - The company operates manufacturing facilities in Statesville, North Carolina, and Bangalore, India, serving both domestic and international markets [5] Product Offerings - Kewaunee's product range includes steel and wood casework, fume hoods, biological safety cabinets, and epoxy resin work surfaces [5] - The company will highlight its new Revit design tools at the Arablab tradeshow, aimed at enhancing lab planning and architectural precision [3] Subsidiary Information - NuAire, acquired by Kewaunee, specializes in biological safety cabinets and other essential laboratory products, with manufacturing facilities in Minnesota and partnerships in the Netherlands and China [6]

Company Overview - Kewaunee Scientific Corporation, founded in 1906, is a global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products [2] - The company's product offerings include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks [2] - Kewaunee's corporate headquarters is located in Statesville, North Carolina, with sales offices in the United States, India, Saudi Arabia, and Singapore [2] - The company operates three manufacturing facilities in Statesville and one in Bangalore, India, serving both domestic and international markets [2] Recent Developments - Kewaunee Scientific announced plans to release its first quarter fiscal year 2026 financial results on September 10, 2025, after the close of trading [1] - The newly acquired subsidiary, Nu Aire, specializes in manufacturing biological safety cabinets, CO2 incubators, ultralow freezers, and other essential laboratory products [3] - Nu Aire, founded in 1971, has its headquarters and manufacturing facilities in Plymouth, Minnesota, with additional capabilities in Long Lake, Minnesota, and a warehouse partnership in the Netherlands [3] Future Outlook - The company is focused on realizing the benefits of the Nu Aire acquisition, which is expected to enhance its product portfolio and market reach [5]

Core Viewpoint - Kewaunee Scientific Corporation (KEQU) has received an upgrade to "Outperform" due to strong acquisition execution, sustained margin improvement, a record backlog providing revenue visibility, and partial insulation from macroeconomic challenges through healthcare exposure [1]. Acquisition Execution & Strategic Fit - The acquisition of Nu Aire, Inc. in November 2024 has resulted in a 30.7% year-over-year increase in domestic segment sales, reaching $179.4 million in fiscal 2025 [2]. - This acquisition has expanded KEQU's product portfolio to include higher-margin products like biological safety cabinets, CO2 incubators, and ultralow freezers, while also establishing new distribution partners in previously underpenetrated markets [3]. - Integration progress has exceeded expectations, creating early cross-selling opportunities and reinforcing KEQU's position as a full-spectrum laboratory solutions provider [3]. Gross Margin Expansion & Profitability Gains - KEQU's gross margin has expanded by 310 basis points to 28.6% in fiscal 2025 from 25.5% in fiscal 2024, driven by Nu Aire's favorable product mix, operational efficiencies, and disciplined cost control, despite incurring $6 million in one-time integration and purchase accounting expenses [4]. - Adjusted EBITDA increased by 28.4% to $26.5 million, representing 10.9% of sales, indicating the company's ability to convert top-line gains into higher operating leverage [5]. - The annuitization of the company's pension obligation in fiscal 2024 has reduced earnings volatility, providing a cleaner base for future margin expansion [5]. Record Backlog & Revenue Visibility - KEQU has a record backlog of $214.6 million at the end of fiscal 2025, up 37.9% from the previous year, providing exceptional near-term revenue visibility, with management expecting 93% of orders to convert into revenues in fiscal 2026 [6]. - The backlog includes diverse end markets such as healthcare, pharmaceuticals, and education, which helps mitigate cyclicality often seen in the broader construction and industrial sectors [6]. - The healthcare and life sciences sectors, enhanced by Nu Aire's capabilities, have shown greater resilience against macroeconomic uncertainty, providing KEQU with a degree of macro immunity [7]. Conclusion - Kewaunee's transformation following the Nu Aire acquisition, along with strong domestic performance, expanding margins, record backlog, and attractive valuation, supports an Outperform rating [10]. - The company is positioned to deliver above-market returns over the next 12 months, with key catalysts including backlog conversion and incremental synergies from the Nu Aire integration [10].

Sales Performance - Sales for fiscal year 2025 were $240.5 million, an increase of 18.0% compared to fiscal year 2024 sales of $203.8 million[108]. - Domestic Segment sales for fiscal year 2025 were $179.4 million, an increase of 30.7% compared to fiscal year 2024 sales of $137.2 million, primarily due to the acquisition of Nu Aire[108]. - International Segment sales for fiscal year 2025 were $61.1 million, a decrease of 8.2% from fiscal year 2024 sales of $66.5 million, attributed to customer site delays in India[108]. Financial Metrics - The order backlog was $214.6 million at April 30, 2025, compared to $155.6 million at April 30, 2024[109]. - Gross profit margin increased to 28.6% in fiscal year 2025 from 25.5% in fiscal year 2024, driven by improved manufacturing productivity and the Nu Aire acquisition[109]. - Operating expenses increased to $51.1 million in fiscal year 2025 from $33.8 million in fiscal year 2024, largely due to the acquisition of Nu Aire[110]. - Net earnings for fiscal year 2025 were $11.4 million, or $3.83 per diluted share, down from $18.8 million, or $6.38 per diluted share, in fiscal year 2024[116]. - The effective income tax rate for fiscal year 2025 was 21.7%, compared to an income tax benefit of 45.3% in fiscal year 2024[114]. Acquisition Details - The Company completed the acquisition of Nu Aire for $55.0 million on November 1, 2024, funded through a combination of seller notes and cash[101]. - In November 2024, the company acquired Nu Aire, enhancing its position in laboratory and biosafety solutions[130]. Cash Flow and Investments - Cash used in investing activities for fiscal year 2025 was $30.9 million, primarily for the acquisition of Nu Aire, with capital expenditures of $2.2 million[124]. - Working capital increased to $64.7 million at April 30, 2025, up from $56.0 million at April 30, 2024, with a current assets to current liabilities ratio of 2.2-to-1.0[126]. - The term loan balance was $13.8 million at April 30, 2025, with interest rates on a floating basis, and no advances under the revolving credit facility[132]. Dividend Policy - The company did not declare or pay any dividends during the last two fiscal years, with future dividends dependent on various factors including earnings and capital requirements[127]. Market Outlook - The company's financial outlook is limited by its role as a subcontractor, with demand dependent on laboratory and healthcare construction projects and raw material costs[129]. - Fiscal year 2025 results reflect strong execution and relationships with dealers, supported by a healthy backlog and improved manufacturing capabilities[131]. Currency Exposure - For fiscal year 2025, 23% of net sales were derived from currencies other than U.S. dollars, indicating exposure to foreign currency exchange risks[133]. - Cash balances of $8.4 million were held by subsidiaries in currencies other than U.S. dollars as of April 30, 2025[135].

Core Viewpoint - Kewaunee Scientific Corporation has demonstrated significant growth in both revenue and earnings for the fourth quarter and fiscal year 2025, outperforming the S&P 500 index during the same period [1][2][3]. Revenue & Earnings Performance - Fiscal fourth-quarter net sales increased by 36.1% to $77.1 million from $56.7 million year-over-year [2]. - Adjusted diluted earnings per share (EPS) rose by 25.8% to $1.95 from $1.55 [2]. - For fiscal 2025, net sales totaled $240.5 million, an 18% increase from $203.8 million in the previous year [3]. - Adjusted diluted EPS for the year rose by 28.2% to $5.37 from $4.19 [3]. Segment Highlights - Domestic operations saw a 54.7% increase in fiscal fourth-quarter sales to $55.5 million from $35.9 million [4]. - International sales grew by 3.9% year-over-year in the fiscal fourth quarter to $21.7 million [5]. - The corporate segment reported an adjusted EBITDA loss of $1.4 million, widening from a loss of $956,000 the previous year [6]. Management Commentary - The CEO attributed the strong performance to effective strategy execution and heightened customer demand [7]. - The company acknowledged macroeconomic challenges but highlighted its adaptable culture and partnerships as strengths [8]. Drivers Behind the Results - The acquisition of Nu Aire significantly contributed to revenue and earnings growth, with adjusted operating profit reaching $9.8 million from $5.6 million in the prior year [9]. - The fiscal fourth-quarter adjusted gross profit surged by 69% to $24.7 million from $14.6 million [10]. Guidance - Management expressed optimism for continued growth through organic initiatives and potential future acquisitions [12]. Other Developments - Kewaunee completed the acquisition of Nu Aire on November 1, 2024, which is expected to generate long-term synergies despite short-term costs [13]. - The acquisition led to an increase in long-term debt and a rise in the debt-to-equity ratio to 0.99-to-1 from 0.70-to-1 the previous year [14].